Diffuse large B-cell lymphoma: open trials in Romania

• NCT06717347

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Onco Card S.R.L., Brasov · Spitalul Clinic Colentina Bucuresti, Bucharest · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu

  Registry updated 2026-10-21

• NCT06980116

  Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

  Trial Treatment · Phase 1 · Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

  Arensia Clinics S.R.L., Bucharest · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca

  Registry updated 2026-08-13

• NCT05544019

  Study of SGR-1505 in Mature B-Cell Neoplasms

  Trial Treatment · Phase 1 · Schrödinger, Inc.

  Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, Bucharest · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca

  Registry updated 2026-02-13

• NCT04920617

  DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  Trial Treatment · Phase 2 · ImmunoVaccine Technologies, Inc. (IMV Inc.)

  Bucharest Oncology Institute "Prof.Dr.Al. Trestioreanu", Bucharest · The Oncology Institute "Prof. Dr. Ion Chiricuţă" I.O.C.H., Cluj-Napoca

  Registry updated 2023-04-07

All Diffuse large B-cell lymphoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error